English
中文简体
中文繁体
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
Company
Overview
Board of Directors
Partnering
Technology
Glycan-specific Conjugation
Alphatecan
Bispecific Antibody
Subcutaneous Formulation
Single-domain Antibody
Publications
Pipeline
Overview
Envafolimab(KN035)
KN026
JSKN003
JSKN016
JSKN033
KN046
KN019
Investors
Information Disclosure
Corporate Governance
Stock Information
Corporate Communications
Email Subscription
News
Press Release
Media Report
Career
Corporate Culture
Job Opportunities
Contact Us
English
中文简体
中文繁体
NEWS
Press Release
Media Report
Year:
Select
2024
2020
2019
2018
2017
Media Report
19
November 2018
ENDPOINTS NEWS
Seeking an edge in the global I/O race, Alphamab Oncology loads up $100M-plus from marquee backers
19
April 2018
BioWorld
KN026, a Her-2 bispecific with best-in-class potential, is moving into clinical development
21
September 2017
BioCentury
Alphamab combines antibody discovery platforms and GMP manufacturing expertise to its pipeline of nanobodies, bispecifics and multi-antibody cocktails.
13
June 2019
BioWorld
KN035, the leading subcu PD-L1 antibody under development, is in clinical trials in the US, Japan and China
1
2
PREV
2/2
NEXT
